Entero Healthcare Solutions Limited has informed the Exchange about temporary suspension of drug licenses of Atreja Healthcare Solutions Private Limited, a wholly Owned Subsidiary of the Company, for a period of three days from 30.01.2026 to 01.02.2026.
ENTERO · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Entero Healthcare Solutions has informed the stock exchange that its wholly owned subsidiary, Atreja Healthcare Solutions Private Limited, has received a temporary suspension of its drug licenses for a period of three days, from January 30, 2026 to February 1, 2026. The duration is short and the cause/reason for suspension has not been disclosed in this filing. The subsidiary continues to remain part of the company, and the suspension is limited to drug license operations only. The company has not indicated any material financial impact at the group level.
This is a minor, short-duration operational disruption at a subsidiary and is unlikely to have a meaningful impact on the company's overall business or stock price. Investors may want to watch for further updates on the reason for suspension and any follow-on regulatory action.